Advertisement

Topics

Pembrolizumab Shows Durable Response in Refractory Cervical Cancer

12:30 EDT 12 Jun 2019 | MedPageToday

(MedPage Today) -- Overall response rate was 12.2% and overall survival was 11 months in PD-L1-positive patients

Original Article: Pembrolizumab Shows Durable Response in Refractory Cervical Cancer

NEXT ARTICLE

More From BioPortfolio on "Pembrolizumab Shows Durable Response in Refractory Cervical Cancer"

Advertisement
Quick Search
Advertisement
Advertisement